Skip to content

Breast cancer risk after modern radiotherapy

Breast cancer risk after modern radiotherapy - CRAMER

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00028896
Enrollment
150
Registered
2022-04-29
Start date
2022-05-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C81 C50.9

Interventions

Group 1: From patients with Hodgkin lymphoma diagnosed since 2006 with upper body-directed radiotherapy treatment retrospective data will be collected on age at treatment, year of treatment, first pri

Sponsors

Medizinische Hochschule Brandenburg Campus GmbH
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Cancer diagnosed as of 2006 with upper body-directed radiotherapy treatment using any technique derived from computer tomography-based treatment planning, 2. Hodgkin, other lymphoma and sarcoma patients have top priority for admission, patients with breast cancer, lung cancer or esophageal cancer with radiotherapy radiation to the breast may be included on an individual basis, 3. all quadrants and the central area of ??both breasts can be delineated on the planning computer tomography are (or have previously been) delineated (according to the study plan below described procedure), 4. the radiotherapy dose can be determined for all quadrants (and the central area) of both breasts, 5. at least one of the breast quadrants / central areas is partially in the radiation field

Exclusion criteria

Exclusion criteria: 1. patients who have received posterior radiotherapy for sarcomas, 2. patients who have received palliative radiotherapy, 3. patients less than 15 years old at the time of cancer diagnosis

Design outcomes

Primary

MeasureTime frame
To obtain absolute breast cancer risk predictions for patients treated with modern radiotherapy plans using prediction models based on quadrant-specific doses and mean doses.

Secondary

MeasureTime frame
To compare field types over time in terms of irradiated volume, prescribed dose, mean dose, and quadrant-specific doses (in combination with data on patients from previous case-control study, Krul et al 2017), and to compare relative breast cancer risks between radiotherapy plans obtained using modern and previously used techniques.

Countries

Germany, Netherlands

Contacts

Public ContactAndré Buchali

Ruppiner Kliniken GmbH

A.buchali@ruppiner-kliniken.de03391-394300

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026